Based on the results obtained, it can be concluded that dual PDE4/7 inhibitors may constitute a safer therapeutic alternative compared to the standard immunosuppressive drugs used for the treatment of AIH as well as other inflammatory and autoimmune disorders. The gene discussed is PDE4A; the disease is autoimmune hepatitis.